Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

706
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
706
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.3K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.3K
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

800
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
800

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of a highly-sensitive, quantitative LC-MS/MS assay to evaluate plasma oxytocin.

Journal of mass spectrometry and advances in the clinical lab·2025
Same author

[Environmental crisis and mental health].

Revue medicale de Liege·2022
Same author

[Deep brain stimulation as a treatment for severe multidrug-resistant obsessive compulsive disorder].

Revue medicale de Liege·2022
Same author

[Obesity and eating disorders].

Revue medicale de Liege·2021
Same author

[The impact of the COVID-19 pandemic on the psychological health of healthcare workers].

Revue medicale de Liege·2020
Same author

[Catatonia, complicated withdrawal from benzodiazepines].

Revue medicale de Liege·2020
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

744

[Antipsychotics in depression].

W Pitchot1, G Scantamburlo, D Souery

  • 1Service de Psychiatrie, CHU de Liège, Belgique. wpitchot@chu.ulg.ac.be

Revue Medicale De Liege
|December 5, 2013
PubMed
Summary
This summary is machine-generated.

Treating depression effectively requires complete remission and recurrence prevention. Adding atypical antipsychotics like aripiprazole and quetiapine XR is a popular strategy for treatment-resistant depression.

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.8K
A New Method for Inducing a Depression-Like Behavior in Rats
07:57

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

21.6K

Related Experiment Videos

Last Updated: May 5, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

744
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.8K
A New Method for Inducing a Depression-Like Behavior in Rats
07:57

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

21.6K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Public Health

Context:

  • Depression is a significant global health concern.
  • Achieving complete remission and preventing recurrence are key treatment goals.
  • Treatment-resistant depression poses a clinical challenge.

Purpose:

  • To explore pharmacological strategies for treatment-resistant depression.
  • To evaluate the role of atypical antipsychotics in achieving remission.
  • To review available scientific data on specific agents.

Summary:

  • Atypical antipsychotics are increasingly used as an add-on therapy for treatment-resistant depression.
  • Clinical trials have investigated second-generation antipsychotics for treatment-resistant and bipolar depression.
  • Evidence exists for the efficacy of aripiprazole and quetiapine XR in these contexts.

Impact:

  • Provides insights into managing difficult-to-treat depression.
  • Highlights the utility of atypical antipsychotics in clinical practice.
  • Informs treatment decisions for patients with treatment-resistant depression.